Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636142 | 0.83 | DGAT1 (0.38) | DGAT1PKMGAATSHRKLKB1 | |
| SCHEMBL27284918 | 0.82 | F2RL1 (0.34) | DGAT1PKMGAATSHRKLKB1 | |
| SCHEMBL10117742 | 0.80 | PKM (0.38) | DGAT1PKMGAATSHRKLKB1 | |
| SCHEMBL30720875 | 0.79 | MAPT (0.44) | DGAT1PKMPOLBMAPT | |
| SCHEMBL4799731 | 0.79 | PTGS2 (0.43) | DGAT1PKMGAATSHRNPC1 | |
| SCHEMBL13560502 | 0.77 | DGAT1 (0.35) | DGAT1TSHRMAPT | |
| SCHEMBL3635281 | 0.76 | DGAT1 (0.35) | DGAT1MAPT | |
| SCHEMBL13560582 | 0.76 | KLKB1 (0.37) | DGAT1PKMGAATSHRKLKB1 | |
| SCHEMBL10117725 | 0.74 | ALDH1A1 (0.38) | DGAT1TSHRNPC1MAPT | |
| SCHEMBL5488835 | 0.74 | NPC1 (0.36) | DGAT1TSHRKLKB1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739393-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2025014788-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | WO | disclosed |
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2594565-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-2594563-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2594564-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8389517-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2166856-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154271-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | SGMS1, SGMS2, CERS2 | DGAT1 49/4885PKM 549/4885GAA 247/4885 |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | DGAT1 54/4885PKM 1378/4885GAA 36/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | DGAT1 49/4885PKM 549/4885GAA 247/4885 |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | DGAT1 118/4885PKM 3504/4885GAA 3/4885 |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | DGAT1 454/4885PKM 2506/4885GAA 177/4885 |
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | ACIN1, REV1, NFATC1 | DGAT1 3822/4885PKM 3160/4885GAA 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.